Premium
Frequent expression of FAS/APO ‐1 in Hodgkin's disease and anaplastic large cell lymphomas FAS/APO ‐1 in Hodgkin's disease and anaplastic large cell lymphomas
Author(s) -
XERRI L.,
CARBUCCIA N.,
PARC P.,
HASSOUN J.,
BIRG F.
Publication year - 1995
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.1995.tb00215.x
Subject(s) - cd30 , anaplastic large cell lymphoma , pathology , immunohistochemistry , lymphoma , reed–sternberg cell , nodular sclerosis , fas receptor , large cell , biology , medicine , cancer research , apoptosis , cancer , programmed cell death , adenocarcinoma , hodgkin lymphoma , biochemistry
FAS/APO‐1 (CD95) is a membrane glycoprotein belonging to the tumour necrosis factor/nerve growth factor receptor family, and which can trigger apoptosis in some lymphoid cell lines. Immunohistochemistry combined with Northern blotting allowed determination of the pattern of FAS/APO‐1 expression in a series of Ki‐1 [CD30] positive lymphoid malignancies, including 27 Hodgkin's disease and eight anaplastic large cell lymphomas. CD30 negative tumours used as controls included 27 B‐cell non‐Hodgkin's lymphomas, 14 T‐cell non‐Hodgkin's lymphomas, four reactive lymphadenitis, and non‐lymphoid tissues. Immunohistochemistry, performed on frozen sections, revealed a strong FAS/APO‐1 expression in 25 out of 27 (92%) Hodgkin's disease cases, predominantly in Reed Sternberg cells; 50 to 100% of the neoplastic cells in eight out of (100%) anaplastic large cell lymphoma cases were positive. In contrast, positive FAS/APO‐1 immunostaining was observed only in 22 out of 41 (53%) CD30 negative non‐Hodgkin's lymphomas. Northern blot analysis detected variable amounts of the FAS/APO ‐1 transcript in the immunohistochemistry‐positive samples. These results suggest possible hyper‐expression of FAS/APO‐1 (CD95) in Hodgkin's disease and anaplastic large cell lymphomas.